About Catalent
Catalent is a company based in Somerset (United States) founded in 2007 was acquired by Novo Holdings in February 2024. Catalent has completed 13 acquisitions, including Accucaps, Bettera and Cook Pharmica. Catalent offers products and services including Oral Dose Development, Softgel Technology, and Inhalation Development. Catalent operates in a competitive market with competitors including Novartis, Surrozen, Curia, AmplifyBio and WuXi Biologics, among others.
- Headquarter Somerset, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Catalent, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$761.61 K (USD), Grant
Oct 01, 2020
-
Investors
JPMorgan Chase
& 3 more
-
Employee Count
Not available
-
Investments & Acquisitions
Accucaps
& 12 more
-
Acquired by
Novo Holdings
(Feb 05, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Catalent
Catalent offers a comprehensive portfolio of products and services, including Oral Dose Development, Softgel Technology, and Inhalation Development.
Services for formulating and enhancing oral drug bioavailability.
Encapsulation solutions for improved drug delivery and stability.
Analytical and formulation services for inhalable drug forms.
People of Catalent
Unlock access to complete
Software Development Team
170 people
Leadership Team
60 people
Operations Team
46 people
Human Resources and Administration
31 people
Product Management Team
28 people
Senior Team
27 people
Legal and Compliance
23 people
Finance and Accounting
21 people
Unlock access to complete
Funding Insights of Catalent
Investors in Catalent
Catalent has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include JPMorgan Chase, European Union and Aisling Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Catalent
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Catalent
Catalent has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Accucaps, Bettera and Cook Pharmica.
Investment portfolio details for Catalent
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vaccine development is advanced by VMIC as a non-profit entity.
|
Locked | Locked | 2018 | Locked | |
|
iPS cells are developed for therapeutics to prevent immune rejection.
|
Locked | Locked | 2017 | Locked | |
|
Services for cell therapy development and manufacturing are provided.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Catalent
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Catalent
Detailed financials for Catalent
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Catalent Comparisons
Peer comparison for Catalent
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Catalent
Catalent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Surrozen, Curia, AmplifyBio and WuXi Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| Locked | Locked | Locked |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| Locked | Locked | Locked |
Drug research, development, testing, and consulting services are provided.
|
|
| Locked | Locked | Locked |
Provides contract research, development, and manufacturing services for biologic drugs.
|
|
| Locked | Locked | Locked |
Protein therapeutics are developed and manufactured by WuXi Biologics.
|
Detailed competitors of Catalent
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Catalent
Complete news archive for Catalent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Catalent
Catalent was founded in 2007.
Catalent is headquartered in Somerset, United States.
Alessandro Maselli is the current CEO of Catalent.
Catalent, backed by 202366937.14725998 from European Union, JPMorgan Chase, Aisling Capital, focuses on providing healthcare solutions, biopharma outsourcing, diversified, and biologics. CDMO offering drug and biologics development services. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
Catalent offers Oral Dose Development, Softgel Technology, and Inhalation Development.
Catalent has made 13 acquisitions, including Accucaps, Bettera, and Cook Pharmica.
Catalent has 4 investors. Key investors include JPMorgan Chase, European Union, Aisling Capital, and Novo Holdings.